Stock COR CENCORA, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Cencora, Inc. Stock

Equities

COR

US03073E1055

Medical Equipment, Supplies & Distribution

Real-time Estimate Cboe BZX
Other stock markets
 12:40:20 2024-12-03 pm EST 		5-day change 1st Jan Change
251.09 USD +0.49% Intraday chart for Cencora, Inc. +0.92% +22.08%
11:14am Cencora Prices $1.8 Billion in Senior Notes Offering MT
Nov. 27 Jefferies Adjusts Price Target on Cencora to $245 From $240 MT
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Exceptional extension!
Enjoy this offer
* See conditions on site

Valuation: Cencora, Inc.

Capitalization 48.29B 46.02B 42.81B 38.19B 67.95B 4,093B 74.78B 532B 197B 1,677B 181B 177B 7,204B P/E ratio 2025 *
20.5x
P/E ratio 2026 * 18.1x
Enterprise value 46.91B 44.71B 41.59B 37.1B 66.01B 3,976B 72.65B 517B 192B 1,629B 176B 172B 6,998B EV / Sales 2025 *
0.15x
EV / Sales 2026 * 0.14x
Free-Float
35.26%
Yield 2025 *
0.86%
Yield 2026 * 0.89%
More valuation ratios * Estimated data

Chart: Cencora, Inc.

Dynamic Chart

Latest news: Cencora, Inc.

Cencora Prices $1.8 Billion in Senior Notes Offering 05:14am MT
Jefferies Adjusts Price Target on Cencora to $245 From $240 Nov. 27 MT
Cencora, Inc. Enters into A Term Credit Agreement Nov. 27 CI
Cencora Files Mixed Shelf Registration Nov. 26 MT
Cencora Insider Sold Shares Worth $12,198,750, According to a Recent SEC Filing Nov. 26 MT
Cencora Insider Sold Shares Worth $5,208,619, According to a Recent SEC Filing Nov. 21 MT
JPMorgan Adjusts Price Target on Cencora to $289 From $287, Maintains Overweight Rating Nov. 19 MT
Quiet before the earnings quake Nov. 18Our Logo
Analyst recommendations: Biogen, HP, Moderna, Shell... Nov. 18Our Logo
Baltimore Wins $266 Million in Lawsuit Against Opioid Distributors Nov. 13 MT
Baltimore Wins $266 Million in Lawsuit Against Opioid Distributors, Reuters Reports Nov. 13 MT
Baltimore wins $266 million in opioid case against distributors Nov. 13 RE
TD Cowen Adjusts Price Target on Cencora to $288 From $263, Keeps Buy Rating Nov. 11 MT
More news

Last Transcript: Cencora, Inc.

Logo Cencora, Inc.
Cencora, Inc., Q4 2024 Earnings Call, Nov 06, 2024
Nov. 06
More transcripts

Analysts' recommendations: Cencora, Inc.

Jefferies Adjusts Price Target on Cencora to $245 From $240 Nov. 27 MT
JPMorgan Adjusts Price Target on Cencora to $289 From $287, Maintains Overweight Rating Nov. 19 MT
Analyst recommendations: Biogen, HP, Moderna, Shell... Nov. 18Our Logo
TD Cowen Adjusts Price Target on Cencora to $288 From $263, Keeps Buy Rating Nov. 11 MT
UBS Adjusts Cencora Price Target to $285 From $275, Maintains Buy Rating Nov. 07 MT
More recommendations

Press Releases: Cencora, Inc.

Cencora Prices $500 Million 4.625% Senior Notes Due 2027, $600 Million 4.850% Senior Notes Due 2029 and $700 Million 5.150% Senior Notes Due 2035 10:50pm BU
Cencora : Sustaining Progress Toward DSCSA Compliance Following FDA Exemptions Nov. 10 PU
Cencora : Advances Specialty Leadership Through Acquisition of Retina Consultants of America Form 8 K Nov. 08 PU
CENCORA : REPORTS FISCAL 2024 FOURTH QUARTER AND YEAR END RESULTS Form 8 K Nov. 06 PU
Cencora : Fourth Quarter 2024 Presentation Nov. 06 PU
More press releases

News in other languages: Cencora, Inc.

Cencora, Inc.: Una dosis de datos y distribución Aug. 20
Angoisses aoûtiennes Aug. 02
En Direct des Marchés : BNP Paribas, Axa, Engie, Apple, Amazon, Intel, Nintendo, Nvidia... Aug. 02
Borsa di Italia: ansie di agosto Aug. 02
Bolsa de Madrid: Las ansiedades de agosto Aug. 02
More news

Quotes and Performance

1 day-0.67%
1 week+2.31%
Current month-0.67%
1 month+6.66%
3 months+4.30%
6 months+10.28%
Current year+21.66%
More quotes

Course Extremes

1 week
246.54
Extreme 246.54
253.27
1 month
231.92
Extreme 231.92
253.27
Current year
204.53
Extreme 204.53
253.27
1 year
195.83
Extreme 195.83
253.27
3 years
117.77
Extreme 117.77
253.27
5 years
72.06
Extreme 72.0583
253.27
10 years
68.38
Extreme 68.38
253.27
More quotes

Managers and Directors: Cencora, Inc.

Director TitleAgeSince
Robert Mauch CEO
 Chief Executive Officer 57 2024-09-30
James Cleary DFI
 Director of Finance/CFO 61 2018-11-08
Pawan Verma CTO
 Chief Tech/Sci/R&D Officer 48 2024-11-03
Manager TitleAgeSince
Steven Collis CHM
 Chairman 62 2016-03-02
Richard Gochnauer BRD
 Director/Board Member 74 2008-09-24
Kathleen Hyle BRD
 Director/Board Member 65 2010-05-12
More insiders

ETFs: Cencora, Inc.

Name Weight AuM 1st Jan change Investor Rating
TRUEMARK ESG ACTIVE OPPORTUNITIES FUND - USD ETF TrueMark ESG Active Opportunities Fund - USD
2.85% 2 M€ +21.73% -
More ETFs: Cencora, Inc.

Other Medical Equipment, Supplies & Distribution

Add to a list
Add to a list

0 selected

To use this feature you must be a member
Log inSign up
 Change 5d. change 1-year change 3-years change Capi. ($)
CENCORA, INC. Stock Cencora, Inc.
-0.67%+2.31%+22.43%+115.78%48.29B
ABBOTT LABORATORIES Stock Abbott Laboratories
-1.65%-1.12%+11.37%-9.01%203B
MEDTRONIC PLC Stock Medtronic plc
0.00%+0.92%+8.19%-19.33%111B
BECTON, DICKINSON AND COMPANY Stock Becton, Dickinson and Company
+0.41%-1.18%-6.48%-7.90%64.42B
HOYA CORPORATION Stock Hoya Corporation
+2.61%+2.38%+22.20%+9.39%45.54B
DEXCOM, INC. Stock DexCom, Inc.
+1.69%+1.90%-31.99%-43.37%30.98B
TERUMO CORPORATION Stock Terumo Corporation
+1.01%+0.10%+31.90%+34.16%30.45B
WEST PHARMACEUTICAL SERVICES, INC. Stock West Pharmaceutical Services, Inc.
-0.93%+0.89%-8.28%-26.23%23.37B
ZIMMER BIOMET HOLDINGS, INC. Stock Zimmer Biomet Holdings, Inc.
-1.43%-0.41%-6.33%-10.11%21.99B
STERIS PLC Stock STERIS plc
-0.09%+1.27%+7.54%-0.80%21.6B
Average +0.30%+0.52%+5.06%+4.26% 60.02B
Weighted average by Cap. +0.36%+0.48%+7.83%+0.64%
See all sector performances

Financials

2025 *2026 *
Net sales 317B 302B 281B 251B 446B 26,891B 491B 3,494B 1,297B 11,019B 1,192B 1,166B 47,337B 337B 321B 298B 266B 474B 28,528B 521B 3,707B 1,376B 11,690B 1,265B 1,237B 50,219B
Net income 2.3B 2.19B 2.04B 1.82B 3.23B 195B 3.56B 25.3B 9.39B 79.79B 8.63B 8.44B 343B 2.6B 2.48B 2.3B 2.05B 3.66B 220B 4.02B 28.61B 10.62B 90.22B 9.76B 9.54B 388B
Net Debt -1.38B -1.32B -1.22B -1.09B -1.94B -117B -2.14B -15.2B -5.64B -47.92B -5.19B -5.07B -206B -2.73B -2.6B -2.42B -2.16B -3.84B -231B -4.23B -30.07B -11.16B -94.84B -10.26B -10.03B -407B
More financial data * Estimated data

Company Profile

Logo Cencora, Inc.
Cencora, Inc. specializes in distributing pharmaceutical products. The group supplies generic and name-brand medications, OTC healthcare products, and home care equipment to healthcare providers (hospitals, clinics, pharmacies, physicians, etc.) located in the United States and Canada. The group also offers services to physicians and patients (support and reimbursement assistance services, prescription management services, nursing services, home injection and perfusion services, etc.).
Employees
44,000
Sector
Medical Equipment, Supplies & Distribution
Calendar
2024-12-04 - Citi Global Healthcare Conference
More about the company

Quotes

Date Price Change Volume
24-12-03 251.02 $ +0.46% 281,717
24-12-02 249.87 $ -0.67% 950,713
24-11-29 251.55 $ +0.74% 1,103,278
24-11-27 249.69 $ +0.50% 906,615
24-11-26 248.45 $ +1.73% 977,982

Delayed Quote Nyse, December 02, 2024 at 04:00 pm EST

More quotes

Income Statement and Estimates

income-statement-evolution-chart CENCORA-INC More financial data

Ratings

Trading Rating
Investor Rating
ESG Refinitiv
B-
surperformance-ratings-light-chart CENCORA-INCMore Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
18
Last Close Price
249.87USD
Average target price
267.32USD
Spread / Average Target
+6.98%
Consensus
Profit revisions
estimates-change-chart CENCORA-INC Estimate revisions

Quarterly revenue - Rate of surprise

quality-estimates-chart CENCORA-INC Company calendar
  1. Stock Market
  2. Equities
  3. COR Stock
Exceptional Extension | BLACK FRIDAY -40% : Unlock Tomorrow's Top Investments with Our Exclusive Subscriber-Only Tools!
d
:
:
BENEFIT NOW